Evaluation of Anti-Inflammatory Effects of Rosiglitazone, a PPAR Gamma Agonist in Models of Acute and Chronic Inflammation and Assessment of its Effect on Gastric Mucosa

Objectives-To evaluate anti-inflammatory activity of rosiglitazone in the acute and chronic models of inflammation. Also to determine ulcerogenic potential on gastric mucosa in Wistar rats in comparison with diclofenac. Methodology-Anti-inflammatory effects of rosiglitazone in the dose of 1, 3 and 10 mg/kg b.wt., i.p were studied in acetic acid-induced peritoneal capillary permeability model in mice and cotton pellet-induced granuloma model in Wistar rats. The dose of rosiglitazone that showed maximum anti-inflammatory effect i.e 10mg/kg b.wt. was chosen to study ulcerogeinc potential. Cotton pellet granuloma model was repeated with the drugs being given orally and effect on inflammation and ulcer index was assessed. Results-All three doses of rosiglitazone did not significantly reduce inflammation in the model of acetic acid-induced peritoneal capillary permeability. However, there was significantly reduced inflammation in a dose dependent manner in the model of cotton pellet granuloma in rats. Rosiglitazone in the dose of 10 mg/kg showed significant reduction in inflammation. Ulcer index with rosiglitazone 10mg/kg was comparable to vehicle. Whereas diclofenac sodium showed statistically significant ulcer index as compared to rosiglitazone. Discussion-In conclusion the results of this study suggest that rosiglitazone has anti-inflammatory effects without ulcerogenic potential and can be useful in inflammatory disorders especially in patients with diabetes mellitus.